港股异动 | 百奥赛图-B(02315)午前涨超6% IDE034首例患者给药 触发500万美元里程碑款项

Core Viewpoint - The stock of Baiaosaitu-B (02315) has seen a significant increase of over 6%, currently trading at 53.35 HKD, with a transaction volume of 28.27 million HKD, following the announcement of a milestone payment related to a clinical trial [1] Group 1: Company Developments - IDEAYA has announced the completion of the first patient enrollment in the Phase I dose escalation/expansion clinical trial for its investigational PTK7/B7H3 bispecific TOP1 antibody-drug conjugate (ADC) IDE034 [1] - The first patient dosing of IDE034 will trigger a milestone payment of 5 million USD from IDEAYA to Baiaosaitu, as per their signed option and licensing agreement [1] - IDE034 is a potentially first-in-class bispecific B7H3/PTK7 TOP1 ADC, developed independently by Baiaosaitu and licensed to IDEAYA in July 2024 [1] Group 2: Regulatory and Market Impact - The project received FDA approval for clinical trials in December last year, marking a significant regulatory milestone for both companies [1] - The IND approval signifies an important step in the collaboration between Baiaosaitu and IDEAYA, laying the groundwork for the subsequent clinical development of IDE034 [1] - This development highlights Baiaosaitu's technical strength in the discovery and development of bispecific ADCs [1]